- Home
- ENTX vs CHEC Comparison
ENTX vs CHEC Comparison
Compare ENTX & CHEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTX | CHEC |
|---|---|---|
| Founded | 2010 | 2024 |
| Country | Israel | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 175.5M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ENTX | CHEC |
|---|---|---|
| Price | $3.14 | $10.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 390.9K | 59.7K |
| Earning Date | 11-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $9.91 |
| 52 Week High | $4.20 | $10.56 |
Technical Indicators
Market Signals| Indicator | ENTX | CHEC |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 72.60 |
| Support Level | $2.76 | $10.22 |
| Resistance Level | $3.56 | $10.47 |
| Average True Range (ATR) | 0.21 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 47.22 | 100.00 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
About CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.